Cargando…
Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions
The standard of care therapy of chronic hepatitis C with the combination of pegylated interferon and ribavirin for 24 or 48 weeks was a remarkable accomplishment of the past decade. However, sustained virological responses rates of about 80% (genotypes 2–3) and 50% (genotype 1) were not satisfactory...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427372/ https://www.ncbi.nlm.nih.gov/pubmed/23490868 http://dx.doi.org/10.1016/j.bjid.2012.10.010 |